Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting ...
Interestingly, the anti-HIV-1 targets of triterpene analogs can vary depending on the side chain modification position. C-28 modified betulinic acid analogs are potent HIV entry inhibitors, while C-3 ...
An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results